Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsORALStandard

ERYTHROMYCIN ETHYLSUCCINATE

ERYTHROMYCIN ETHYLSUCCINATE

Standard Dose
EQ 400MG BASE/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Prescription
  • Approval overview ERYTHROMYCIN ETHYLSUCCINATE is listed in Drugs@FDA under application 216212 (ANDA).
  • Review priority: STANDARD Marketing status: Prescription Active ingredient ERYTHROMYCIN ETHYLSUCCINATE Form and strength GRANULE;ORAL - EQ 400MG BASE/5ML Sponsor CADILA PHARMS LTD Submission history Latest submission status date: 2022-11-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERYTHROMYCIN ETHYLSUCCINATE is listed in Drugs@FDA under application 216212 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ERYTHROMYCIN ETHYLSUCCINATE Form and strength GRANULE;ORAL - EQ 400MG BASE/5ML Sponsor CADILA PHARMS LTD Submission history Latest submission status date: 2022-11-21 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.